Atlas Trials

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Clinical trial NCT05206656 · COMPLETED

Trial details

NCT number
NCT05206656
Sponsor
Hunan Cancer Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2020-10-09
Primary completion
2022-04-30
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.